Gene mutation in AML with poor prognosis all except:
**Core Concept**
The question is testing the student's knowledge of specific gene mutations in Acute Myeloid Leukemia (AML) that are associated with a poor prognosis. AML is a type of cancer characterized by the rapid growth of abnormal white blood cells, which can interfere with the production of normal blood cells.
**Why the Correct Answer is Right**
Gene mutations play a crucial role in the development and progression of AML. Certain mutations confer a poor prognosis, making them a critical factor in treatment decisions. The NPM1 mutation is often associated with a favorable prognosis, whereas mutations in the TP53 gene are generally linked to a poor outcome. The NPM1 mutation leads to the production of a constitutively active protein, disrupting normal cell cycle regulation. In contrast, TP53 mutations result in the loss of function of the p53 tumor suppressor protein, allowing cells with DNA damage to survive and proliferate.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because the NPM1 mutation is associated with a favorable prognosis in AML patients.
* **Option B:** This option is incorrect because the TP53 mutation is indeed associated with a poor prognosis in AML patients.
* **Option C:** This option is incorrect because the ASXL1 mutation is associated with a poor prognosis in AML patients, similar to the TP53 mutation.
* **Option D:** This option is incorrect because the FLT3-ITD mutation is associated with a poor prognosis in AML patients, often leading to resistance to chemotherapy.
**Clinical Pearl / High-Yield Fact**
In AML, the presence of a NPM1 mutation can influence treatment decisions and prognosis. Patients with a NPM1 mutation may be more likely to respond to certain therapies, such as azacitidine or decitabine.
**Correct Answer:** A.